Abstract: A use of a ferroptosis inhibitor in preparation of a drug for treating gastritis is provided. The ferroptosis inhibitor includes ferrostatin-1 or a derivative, isomer, or pharmaceutically acceptable salt thereof as an active ingredient, and further includes a pharmaceutically acceptable carrier, an excipient, a diluent, an adjuvant, a vehicle, or a combination thereof. The present disclosure discovers that the ferroptosis inhibitor ferrostatin-1 can effectively inhibit a pathological process of chronic atrophic gastritis (CAG), and in vivo and in vitro experiments confirm that the ferroptosis inhibitor ferrostatin-1 can be used for prevention and treatment of CAG, which can provide a new idea for development and innovation of drugs for treating CAG.

Abstract: A simulation method for a chronic atrophic gastritis (CAG) lesion includes: (1) taking a metaplasia lesion stage as a simulation object, (2) selecting a simulation form of spasmolytic polypeptide-expressing metaplasia (SPEM), and (3) conditionally deleting gene associated with retinoid-IFN-induced mortality-19 (GRIM-19) from gastric mucosal parietal cells. The present disclosure successfully simulates the SPEM, an initial metaplasia response after a gastric mucosal injury and the initial metaplasia response can progress into intestinal metaplasia (IM) and even gastric cancer (GC) under the continuous stimulation of chronic inflammation.

Abstract: Provided is the use of a primer and probe combination and a kit thereof in HBV detection. The primer and probe combination is selected from at least one of an S gene region primer and probe combination, a C gene region primer and probe combination, and an X gene region primer and probe combination. Primers and probes are respectively designed in conserved sequences of the S, C and X genomes of the hepatitis B virus, and a fluorescent quantitative PCR technique is used to simultaneously detect HBV DNA in the same tube.